338 filings
Page 15 of 17
8-K
ef5dyte1
9 Jan 14
Sorrento Therapeutics Appoints Amar Singh as Executive Vice President and Chief Business Officer
12:00am
8-K
mp7be2j
20 Dec 13
Sorrento Therapeutics Completes Acquisition of Concortis Biosystems
12:00am
8-K
c7xxcrpj
19 Nov 13
Regulation FD Disclosure
12:00am
8-K
d1rpddyo
14 Nov 13
Sorrento Enters into Definitive Agreement to Acquire
12:00am
8-K
z7mzzzzfrrc1
12 Nov 13
Entry into a Material Definitive Agreement
12:00am
8-K
y2ksv6j8
25 Oct 13
Sorrento Therapeutics Announces Pricing of Public Offering of 4,150,000 Shares of Common Stock and Listing on NASDAQ
12:00am
8-K
uvtmvvv
21 Oct 13
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
12:00am
8-K
h9e9o
15 Oct 13
Other Events
12:00am
8-K
em0 836rt5k8
11 Oct 13
Sorrento Therapeutics Acquires Clinical Stage Drug Candidate for Treatment of Chronic Pain
12:00am
8-K/A
km0bj8
7 Oct 13
Financial Statements and Exhibits
12:00am
8-K
orxi8izleloyoz0zx
4 Oct 13
Regulation FD Disclosure
12:00am
8-K
te5ajqgzrg5ewmzi
2 Oct 13
Entry into a Material Definitive Agreement
12:00am
8-K/A
z2h 3i9m8jq
30 Sep 13
Index to Financial Statements
12:00am
8-K
lcy9x7 mff
11 Sep 13
Sorrento Therapeutics Completes IgDraSol Merger
12:00am
8-K
6p0nhoh6
8 Aug 13
Sorrento Therapeutics, Inc. Licenses Lonza’s GS Xceed™ Gene Expression System for the Research and Development of Human Therapeutic Antibodies
12:00am
8-K
nfk9xm9lh tmn
5 Aug 13
Sorrento Therapeutics and IGDRASOL Proceed with Development of Cynviloq™ under 505(b)(2) Bioequivalence Regulatory Pathway
12:00am
8-K
n98k bui25bx0
1 Aug 13
Sorrento Therapeutics Announces Reverse Split of Common Stock
12:00am
8-K
x75z7s kanxe2
12 Jul 13
Entry into a Material Definitive Agreement
12:00am
8-K
l8acrb
6 Jun 13
Jefferies 2013 Global Healthcare Conference
12:00am
8-K
343n8262jrn9pmoz2ru
14 May 13
Entry into a Material Definitive Agreement
12:00am